Leerink Partnrs Comments on Benitec Biopharma Inc.’s FY2024 Earnings (NASDAQ:BNTC)

Benitec Biopharma Inc. (NASDAQ:BNTC) – Research analysts at Leerink Partnrs issued their FY2024 EPS estimates for shares of Benitec Biopharma in a report issued on Monday, July 22nd. Leerink Partnrs analyst M. Foroohar forecasts that the biotechnology company will earn ($5.45) per share for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Benitec Biopharma’s current full-year earnings is ($6.56) per share. Leerink Partnrs also issued estimates for Benitec Biopharma’s Q4 2024 earnings at ($0.53) EPS, FY2025 earnings at ($1.81) EPS and FY2026 earnings at ($1.83) EPS.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($1.64) earnings per share for the quarter.

Several other brokerages also recently issued reports on BNTC. Piper Sandler initiated coverage on shares of Benitec Biopharma in a research report on Thursday, June 13th. They issued an “overweight” rating and a $30.00 price objective for the company. JMP Securities raised their target price on Benitec Biopharma from $10.00 to $16.00 and gave the company a “market outperform” rating in a research note on Monday, April 22nd. Finally, SVB Leerink began coverage on Benitec Biopharma in a research note on Monday. They issued an “outperform” rating and a $13.00 price target on the stock.

Benitec Biopharma Price Performance

BNTC stock opened at $9.13 on Wednesday. The firm has a market cap of $85.55 million, a P/E ratio of -4.91 and a beta of 0.91. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.18 and a current ratio of 4.18. Benitec Biopharma has a 1 year low of $1.86 and a 1 year high of $10.88. The stock has a 50-day simple moving average of $8.36 and a 200-day simple moving average of $6.16.

Institutional Investors Weigh In On Benitec Biopharma

An institutional investor recently raised its position in Benitec Biopharma stock. Janus Henderson Group PLC increased its holdings in Benitec Biopharma Inc. (NASDAQ:BNTC) by 35.5% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 244,491 shares of the biotechnology company’s stock after buying an additional 64,092 shares during the period. Janus Henderson Group PLC owned about 9.44% of Benitec Biopharma worth $1,266,000 as of its most recent filing with the SEC. 52.19% of the stock is currently owned by institutional investors and hedge funds.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.